Cell line · CVCL_0455
Papers51
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The CLEC7A Y238∗ variant and susceptibility to pneumonia: a prospective population-based cohort study and mechanistic investigation. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| E3 Ubiquitin Ligase Mind Bomb 1 is a Novel Negative Regulator of Tumor-Suppressive BMP Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of LIMK by Cofilin-1 peptidomimetics enhances actin depolymerization and reduces metastasis of non-small cell lung cancer. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ADCE-T02: A Next-generation Antibody-Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein. | Cell Mol Life Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cathepsin C correlates with M2 macrophage infiltration and regulates the tumor growth and metastasis in non-small cell lung cancer. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Substituents introduction of methyl and methoxy functional groups on resveratrol stabilizes mTOR binding for autophagic cell death induction. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling. | Front Mol Biosci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A New Renieramycin T Right-Half Analog as a Small Molecule Degrader of STAT3. | Mar Drugs | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer. | J Exp Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Intermittent MEK Inhibition with GITR Costimulation Rescues T-cell Function for Increased Efficacy with CTLA-4 Blockade in Solid Tumor Models. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition. | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0455/papers